Two diets and one fibre beat most supplements, and peppermint oil is the herb with the best data.
IBS is a disorder of gut-brain interaction: the gut is structurally normal and behaves abnormally, with pain, bloating and a changed bowel habit. Three interventions have the best evidence, and none of them is exotic.
The low-FODMAP diet. FODMAPs are fermentable oligo-, di-, monosaccharides and polyols — short-chain carbohydrates that draw water and ferment in the colon. A low-FODMAP diet has randomised trial evidence for symptom improvement in IBS, and the effect size is larger than most supplements produce. The important caveat is the procedure: it is a three-phase protocol (strict elimination 4-6 weeks, then structured reintroduction to identify personal triggers, then long-term personalisation) and it should be done with a dietitian. A permanently restricted low-FODMAP diet narrows the diet, changes the microbiome, and is not the treatment.
Soluble fibre — psyllium specifically. Psyllium improves symptoms in IBS, whereas insoluble bran often worsens them. This distinction matters: "eat more fibre" is wrong advice for IBS in general, and psyllium is the fibre with the trials.
Peppermint oil. Covered on its own page; the pooled finding is superiority over placebo with low certainty and more adverse events (mostly reflux). Enteric-coated capsules.
Probiotics. Pooled analyses find a modest benefit, with the honest caveats that strains differ, preparations are unstandardised, and the trials are heterogeneous. A reasonable trial for 4 weeks, then decide on the person's own record.
What the person can do without any of this. A written symptom-and-food diary over 4-6 weeks, eating regular meals, reducing caffeine and alcohol, and treating the stress axis seriously — gut-directed hypnotherapy and cognitive behavioural therapy both have randomised evidence in IBS, which is unusual and worth knowing about, and neither is a "just relax" dismissal.
The red flags are the reason IBS is a diagnosis of exclusion. IBS should not be diagnosed in someone with bleeding, weight loss, anaemia, or new symptoms over 50 without the alternatives being excluded.
Meta-Analysis2025The lancet. Gastroenterology & hepatology
Efficacy of dietary interventions in irritable bowel syndrome: a systematic review and network meta-analysis.
In terms of dietary interventions for IBS, the most evidence exists for a low FODMAP diet, but other promising therapies are emerging and should be the subject of further study.
PubMed 40258374 ↗
Meta-Analysis2025The Lancet. Child & adolescent health
Efficacy of interventions for the treatment of irritable bowel syndrome, functional abdominal pain-not otherwise specified, and abdominal migraine in children: a systematic review and network meta-analysis.
Hypnotherapy and CBT show moderate certainty for treatment efficacy with clinically relevant effect sizes.
PubMed 40246358 ↗
Meta-Analysis2024Nutrients
The Efficacy of Probiotics, Prebiotics, Synbiotics, and Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.
However, the most effective probiotic combination or strain remains unclear, while prebiotics and synbiotics did not show significant improvement.
PubMed 38999862 ↗
Meta-Analysis2023Gastroenterology
Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis.
However, certainty in the evidence for efficacy by GRADE criteria was low to very low across almost all of our analyses.
PubMed 37541528 ↗
Meta-Analysis2023Nutrients
Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.
This study provided the first ranking of outcome-specific efficacy of different probiotic strains and combinations in IBS.
PubMed 37686889 ↗
Meta-Analysis2023The Cochrane database of systematic reviews
Probiotics for management of functional abdominal pain disorders in children.
The results from this review demonstrate that probiotics and synbiotics may be more efficacious than placebo in achieving treatment success, but the evidence is of low certainty.
PubMed 36799531 ↗